| US 7,589,064 B2 | ||
| Formulations of ramipril | ||
| Reynir Eyjolfsson, Hafnarfjordur (Iceland) | ||
| Assigned to Actavis Group hf., (Iceland) | ||
| Filed on Jul. 13, 2007, as Appl. No. 11/777,849. | ||
| Application 11/777849 is a continuation of application No. 10/593627, previously published as PCT/IS2005/000008, filed on Mar. 23, 2005. | ||
| Claims priority of application No. 7196 (IS), filed on Mar. 24, 2004; and application No. 7772 (IS), filed on Mar. 23, 2005. | ||
| Prior Publication US 2007/0254030 A1, Nov. 01, 2007 | ||
| Int. Cl. A61K 38/00 (2006.01) | ||
| U.S. Cl. 514—16 | 14 Claims |
| 1. A tablet formulation comprising:
a) 1.25 mg ramipril, wherein the amount of ramipril is 0.5-1.5% w/w,
b) 85-90% w/w of calcium sulphate dihydrate,
c) 0.5-1.5% w/w of sodium hydrogen carbonate,
d) 7-13% w/w starch pregelatinised, and
e) 0.5-1.5% w/w sodium stearyl fumarate.
|